StageZero Life Sciences Ltd. (SZLSF)

OTCMKTS · Delayed Price · Currency is USD
0.0240
-0.0024 (-9.27%)
Jun 25, 2025, 3:14 PM EDT

StageZero Life Sciences Company Description

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe.

Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood.

The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood.

It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests.

The company is based in Richmond Hill, Canada.

StageZero Life Sciences Ltd.
Country Canada
Industry Diagnostics & Research
Sector Healthcare
Employees 40
CEO James Howard-Tripp

Contact Details

Address:
70 East Beaver Creek Road
Richmond Hill, Ontario L4B 3B2
Canada
Website stagezerolifesciences.com

Stock Details

Ticker Symbol SZLSF
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
ISIN Number CA8525403017
SIC Code 8011

Key Executives

Name Position
James R. Howard-Tripp Executive Chairman and Chief Executive Officer
Dr. Choong-Chin Liew Ph.D. Co-Founder
Warren Whitehead C.M.A., CPA Chief Accountant